November 19, 2026

a2 Milk is growing again on the same China bet that burned it

A parent prepares a baby bottle with formula on a wooden table in a cozy kitchen setting.

The a2 Milk Company is back in growth mode, and that is good news for one of the NZX’s most closely watched exporters. At its annual meeting it told shareholders it expects revenue to top $2 billion in FY27, the year to June 2027, hitting a medium-term target it narrowly missed last year.

The catch is where that $2 billion comes from. The comeback still runs through Chinese infant formula, the same channel that blew a hole in the company’s second half. Diversification into South East Asia and the Middle East is real and growing fast, but it is not yet big enough to change the risk profile.

A target missed by a whisker

FY26 revenue came in at $1.97 billion, up 12.4%, while net profit after tax slipped 5.8% to $207.5 million. Chief executive David Bortolussi says the company “just fell short” of $2 billion and now expects to get there this year.

The FY27 guidance is modest rather than triumphant. Management is forecasting mid-single-digit revenue growth, heavily weighted to the second half, with first-half revenue slightly lower and underlying earnings “materially down” on a year earlier. Full-year underlying EBITDA margin is expected at approximately 15%, with roughly $15 million of one-off Pokeno transformation costs and about $70 million of capital spending built in.

The stock-out that cost a year

The trouble started in the fourth quarter of FY26. Freight problems, a production backlog at Synlait, longer product-release times and extra Chinese customs and testing requirements left shelves empty. Customers did what parents do when their formula disappears, they switched brands.

The damage shows up clearly in the annual report. China-label infant formula revenue fell 14.0% to $544.3 million for the year, with a 6.5% first-half gain wiped out by a 33.0% second-half collapse.

Recovery is under way but only half done. China-label offtake is back to approximately 50% of pre-disruption levels, up from about 40% in August. Bortolussi told shareholders that winning back share “largely depends on our ability to regain past users, new user recruitment momentum” and the performance of two newly launched China-label products, though he said early progress has been positive.

More telling is what management is not doing. Distribution is being held at about two-thirds of previous levels to protect retail sell-through and avoid excess stock. That is a company treating China with caution, not one declaring the problem solved.

Follow the growth bridge

The clearest evidence sits in a2’s own annual meeting slides. Its bridge from $1.21 billion in FY21 to roughly $2 billion in FY27 credits China-label formula with $0.4 billion of growth, English-label formula $0.3 billion and China other nutritionals $0.2 billion. Emerging markets, Australia and New Zealand, and the US contribute $0.1 billion each.

Put simply, China-label infant formula on its own adds more than all the new-market expansion combined, and China-linked products dominate the total.

There is a sound reason for the dependence. China is roughly half the global infant formula category, and the segment a2 owns is growing. In FY26 the overall China-label market was down 0.2% in value, but A2-type protein grew 7% to 22% of the category. The market is also consolidating, with the top five brands holding 59% of market value. Being a scale player in a premium niche of the world’s biggest market is a strong position. It is just not a diversified one.

Vietnam is the bright spot, not the hedge

The under-told part of the story is genuinely encouraging. Vietnam is starting to scale, with distribution in more than 3,500 stores and second-half sales up 128%. The Philippines, Singapore, Malaysia, Indonesia, the UAE and Saudi Arabia are next.

Those growth rates are impressive, but they come off a small base. A $0.1 billion contribution from emerging markets will not cushion another China disruption. For that, these markets need to grow from footnotes into a meaningful share of revenue, which is a two-to-three-year project at best.

Owning the factory changes the odds

The most important structural fix is on the supply side. a2 is moving a2 Platinum production from Synlait to its own Pokeno plant, with Synlait manufacturing for a2 due to end in December. Pokeno holds two China-label registrations, giving a2 direct control over the supply chain that failed it last year.

That directly addresses a risk flagged well before the stock-out. In 2025, Morningstar analyst Angus Hewitt noted that China made up the vast majority of a2’s earnings and that investors worried about reliance on just two major suppliers, along with competition from Nestle and Danone and the risk of Chinese regulatory shifts. Most of that played out in FY26.

The lesson for every premium exporter

For NZ exporters selling premium consumer goods into one dominant market, a2 is a live case study. Bringing manufacturing in-house was the right call, and the return to growth is earned. But hitting $2 billion this year will mostly prove that Chinese parents are coming back. The real test is whether Vietnam, the Philippines and the Gulf can carry enough weight by FY29 that the next customs rule change in Beijing is a bad quarter rather than a lost year.

Sources

Reader Poll · 6 questions

Do you agree or disagree with the following?

Community

Join the discussion

Add useful context, ask a good question, or challenge an idea — keep it specific and respectful.

Create a commenter account

Enter the name you want shown publicly and your email. We will email you a password-set link; you cannot comment until you use it.

Your email is used for sign-in and account security. It is not published with comments.

Subscribe for weekly news

Subscribe For Weekly News

* indicates required